Why Empahert-25 Is Effective for Type 2 Diabetes: Understanding Empagliflozin?

Empahert-25 contains Empagliflozin, an SGLT-2 inhibitor that helps manage type 2 diabetes by reducing the reabsorption of glucose in the kidneys and increasing its excretion through urine. This unique mechanism helps lower blood sugar levels effectively when combined with a healthy diet and regular exercise. Suitable for adults and children aged 10 years and older with type 2 diabetes, Empahert-25 not only supports better glycemic control but also offers additional cardiovascular benefits. Studies have shown that Empagliflozin can help reduce the risk of cardiovascular death in adults with type 2 diabetes who have established cardiovascular disease, making it a valuable treatment option for comprehensive diabetes management.